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Background: The objective of this study was to assess the safety, tolerability, and preliminary 
efficacy of NGX-4010, a capsaicin 8% patch, following pretreatment with three different topical 
anesthetics in patients with peripheral neuropathic pain.
Methods: This open-label, multicenter study enrolled 117 patients with post-herpetic 
  neuralgia, HIV-associated distal sensory polyneuropathy, or painful diabetic neuropathy. 
Patients received pretreatment with one of three lidocaine 4%-based topical anesthetics 
(L.M.X.4® [Ferndale Laboratories Inc, Ferndale, MI], Topicaine® Gel [Estela Basso, Jupiter, 
FL], or Betacaine Enhanced Gel 4 [Tiberius Inc, Tampa, FL]) for 60 minutes followed by a 
single 60- or 90-minute NGX-4010 application, and were followed for 12 weeks. Tolerability 
and safety measures included “pain now” Numeric Pain Rating Scale (NPRS) scores, dermal 
assessments, medication use for treatment-related pain, adverse events (AEs), clinical laboratory 
  parameters, physical examinations, and vital signs. The primary efficacy variable was the 
  percentage change in mean NPRS scores for “average pain for the past 24 hours” from baseline 
to weeks 2 through 12.
Results: Treatment with NGX-4010 following pretreatment with any of the three topical 
anesthetics was generally safe and well tolerated. Nearly all patients completed $90% of the 
planned NGX-4010 application duration. The most common treatment-related AEs, application-
site burning and application-site pain, were transient, mostly mild or moderate, and could be 
adequately managed by local cooling or short-acting oral opioid analgesics. Although slightly 
more patients used medication for treatment-related discomfort following pretreatment with 
Topicaine compared with L.M.X.4 or Betacaine, there were no statistical differences between 
the topical anesthetics. Neuropathic pain reduction from baseline to weeks 2 through 12 was 
approximately 30% and was similar among the topical anesthetics; the proportion of responders 
ranged from 45% to 50%.
Conclusion: Treatment with NGX-4010 following pretreatment with any of the three topical 
anesthetics was generally safe and well tolerated; no significant differences in the parameters 
measured were noted between the pretreatment groups.
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Background
Neuropathic pain is a common condition that affects up to 8% of the European 
population.1–3 Established treatments for neuropathic pain are limited as they provide 
only partial pain relief in an estimated 40%–60% of patients, and many are associated 
with a variety of unwanted systemic effects and intensive daily regimens.4–7
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Capsaicin, the main active capsaicinoid ingredient of 
chilies (Capsicum spp.), is an agonist of the transient receptor 
potential vanilloid 1 (TRPV1) receptor,8 which is highly 
expressed on nociceptors.5,9,10 NGX-4010 is a localized 
dermal delivery system containing high-concentration 
capsaicin (8% w/w) that is designed to rapidly deliver 
therapeutic doses of capsaicin locally into the skin. This 
results in defunctionalization of TRPV1-expressing sensory 
nerve endings and reduced epidermal nerve fiber density.11–14 
Prolonged relief of neuropathic pain for up to 12 weeks 
  following a single NGX-4010 application has been observed 
in patients with post-herpetic neuralgia (PHN) or painful 
HIV-associated distal sensory polyneuropathy (HIV-DSP) 
in Phase II and III studies.15–20
Due to the irritancy of capsaicin, topical application is 
associated with pain, erythema, and other application-site 
reactions.15–20 Because of this, a topical anesthetic is applied 
to reduce application-site discomfort prior to administration 
of NGX-4010. In the above clinical studies, a 4% lidocaine 
topical anesthetic cream (L.M.X.4®/ELA-Max4; Ferndale 
Laboratories Inc, Ferndale, MI) was applied for 60 minutes 
and removed prior to NGX-4010 application. The current 
open-label study sought to determine whether similar toler-
ability could be achieved with other commonly available 4% 
lidocaine formulations and assessed the safety, tolerability, 
and efficacy of NGX-4010 following pretreatment with either 
L.M.X.4 or the alternative products (Topicaine® Gel [ESBA 
Laboratories Inc, Jupiter, FL] or Betacaine Enhanced Gel 4 
[Theraderm Inc, Tampa, FL]).
Methods
Patients
The study was approved by a central institutional review board 
(BioMed IRB, San Diego, CA) or a local  institutional review 
board at participating sites and conducted in   accordance 
with the ethical principles of the Declaration of Helsinki, 
Good Clinical Practice guidelines, and   applicable   regulatory 
requirements. Written informed consent was obtained from 
all participating patients before initiating study-related 
  procedures. The study is registered at c  linicaltrials.gov 
(identifier NCT00082316).
Patients were at least 18 years old with moderate to severe 
neuropathic pain (average Numeric Pain Rating Scale [NPRS] 
score of 3–8 inclusive) for at least 3 months secondary to 
painful diabetic neuropathy (PDN), PHN, or HIV-DSP. The 
NPRS is an 11-point scale (0–10), with 0 indicating no pain 
and 10 indicating the worst possible pain.21 Patients taking 
chronic pain medications (anticonvulsants,   nonselective 
serotonin reuptake inhibitor [SSRI] antidepressants, or 
  opioids) had to be on a stable dose for at least 21 days 
before study patch application and remain on a stable dose 
  throughout the 12-week study.
Exclusion criteria included the following: use of any 
topically applied pain medication on the painful area within 
21 days before study patch application; history of diabetic 
foot ulcerations and/or status post-amputation; any implanted 
medical device for the treatment of neuropathic pain; 
  significant ongoing or recurrent pain of another etiology 
that interfered with judging neuropathic pain; evidence of 
another contributing or immunologic cause for the sensory 
neuropathy; and neuropathic pain areas located only on the 
face, above the scalp hairline, or near mucous membranes.
Procedures
Patients were randomized to receive pretreatment for 
60   minutes with one of three lidocaine 4%-based topi-
cal anesthetics: L.M.X.4, Topicaine Gel, or Betacaine 
Enhanced Gel 4 followed by a 60- or 90-minute treatment 
with NGX-4010 (QUTENZA®; NeurogesX Inc, San Mateo, 
CA). Up to four NGX-4010 patches of 280 cm2 could be 
used (maximum treatment area of 1120 cm2). Patients were 
randomly assigned to receive 60 or 90 minutes of treat-
ment with NGX-4010 and allocated to one of three topical 
anesthetic arms according to a 1:1:1:1:1:1 randomization 
scheme generated by ICON Clinical Research (Redwood 
City, CA). Oxycodone oral solution (1 mg/mL) could be 
administered at the onset of treatment-associated discomfort 
and as needed in the clinic on treatment days. After patch 
removal, local cooling (such as cold compresses) could 
also be used to relieve treatment-associated discomfort. 
In addition, patients could take hydrocodone bitartrate/
acetaminophen (5 mg/500 mg) for up to 5 days after patch 
application for treatment-associated discomfort as needed. 
Topical pain medications were not permitted. Throughout 
the study, patients were allowed to take acetaminophen up 
to 2 g/day as needed for pain.
Safety
Safety was assessed by adverse events (AEs), which were 
coded using the Medical Dictionary for Regulatory   Activities, 
version 7.0. Treatment-associated erythema, discomfort, and 
pain on the day of treatment were not captured as AEs but 
reported as dermal assessment scores or NPRS scores.
Dermal assessment scores (0- to 7-point severity score)22 
were recorded on the day of treatment before and after 
application of topical anesthetic, and 5 and 120 minutes 
after patch removal and at each study visit. The distribution 
of maximum score between the pooled L.M.X.4 group and 
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the other two pooled anesthetic groups was compared using 
the Cochran–Mantel–Haenszel test.
On the day of treatment, “pain now” NPRS scores 
were recorded immediately prior to anesthetic application; 
30 and 55 minutes after anesthetic application; 25, 55, and 85 
(if applicable) minutes after patch application; and 5, 25, 55, 
85, and 115 minutes after patch removal. The change in NPRS 
scores from the pre-anesthetic time point, change in vital 
signs (systolic blood pressure, diastolic blood pressure, heart 
rate, and respiratory rate) from the pre-patch time point, the 
proportion of patients with a $33% increase in NPRS score 
from baseline during the first 48 hours after NGX-4010 treat-
ment, and the proportion of patients with ,90% of intended 
patch application duration were summarized. A Cochran–
Mantel–Haenszel test adjusted for treatment duration (60 or 
90 minutes) was used to test for a difference in the proportion 
of patients with a $33% increase in NPRS score from baseline 
during the first 48 hours between the pooled L.M.X.4 group 
and the other two pooled anesthetic groups.
Descriptive statistics were calculated for laboratory 
parameters and vital signs at screening, termination, and 
change from screening to termination.
A chi-squared test was performed to test for a difference 
in the proportion of patients using medication for treatment-
related discomfort between the pooled L.M.X.4 group and 
the other two pooled anesthetic groups.
A total of 126 subjects were planned for this study. The 
sample size was determined based on a chi-squared continuity 
corrected test to detect a difference of 20% in the proportion 
of subjects completing at least 90% of intended duration 
between the L.M.X.4-treated group and each of the other 
topical anesthetic groups at the 0.05 significance level with 
80% power.
Efficacy
Efficacy was evaluated using NPRS scores for “average pain 
for the past 24 hours” recorded daily at 9 PM in a paper 
diary throughout the study period. Patient Global Impression 
of Change (PGIC; patients reported how they felt after treat-
ment as compared with before treatment on a scale of −3, 
indicating “very much worse,” to +3, indicating “very much 
improved,” with 0 being “no change”) and the investigator-
rated Clinical Global Impression of Change (CGIC)23 were 
evaluated at weeks 2, 6, and 12.
The primary efficacy endpoint was the percentage 
change in “average pain for the past 24 hours” NPRS scores 
from baseline to weeks 2 through 12. To avoid the potential 
confounding effect of allowed opioid medications during 
days 0–5, week 1 scores were not included. Other efficacy 
  measures included: mean absolute changes in NPRS scores 
and the proportion of patients with a $30% or $50% reduc-
tion in NPRS score from baseline to weeks 2 through 12; 
and the percentage of patients considered improved (slightly, 
much, or very much) on the PGIC or CGIC at week 12.
All patients who received any study treatment and had 
at least 3 days of available NPRS scores during the baseline 
period were included in the efficacy analyses. An analysis of 
covariance model with baseline pain score as the covariate 
was used to test for differences in change from baseline to 
weeks 2 through 12 between the pooled L.M.X.4 group and 
each of the other two pooled anesthetic groups. A logistic 
regression model, with the baseline NPRS score as covari-
ate, was performed to test for a difference in the proportion 
of patients reaching 30% and 50% decreases from baseline 
between the pooled L.M.X.4 group and each of the other two 
pooled anesthetic groups.
Results
Patients
A total of 117 patients were enrolled and received NGX-
4010 treatment: 39 were pretreated with L.M.X.4, 38 with 
  Topicaine, and 40 with Betacaine (Figure 1). Fourteen 
patients (12%) terminated the study early; the number of 
  early-terminating patients was similar among the three groups. 
No patients withdrew due to an AE. Six patients   terminated 
early because of unsatisfactory therapeutic response, two 
from each topical anesthetic group.
The average age of patients enrolled in the studies ranged 
from 58 to 63 years (Table 1). The majority of patients were 
white, male, and had PDN. The average duration of pain 
ranged from 3.8 to 5.3 years, and baseline average pain scores 
ranged from 5.4 to 5.9. Slightly more than half of the patients 
were receiving concomitant neuropathic pain treatment 
consisting of anticonvulsants, non-SSRI antidepressants, or 
opioids at baseline.
Safety
NGX-4010 was well tolerated regardless of the   pretreatment 
used. The proportion of patients completing at least 90% 
of the planned NGX-4010 patch application duration 
was 100% for Betacaine, 97% for L.M.X.4, and 97% for 
Topicaine. One patient pretreated with L.M.X.4 had NGX-
4010 i  nadvertently removed after 55 minutes instead of 
the intended 90 minutes, and one patient pretreated with 
  Topicaine had NGX-4010 removed after 30 minutes instead 
of the intended 60 minutes, due to intolerability.
The proportion of patients with at least one AE 
ranged from 50% to 59% (Table 2). AEs were   primarily 
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  capsaicin-related application-site events, which were 
reported by 30%–37% of patients. Common application-site 
events included application-site burning and application-
site pain. Application-site events were transient, resolved 
within 1 or 2 days, and were mostly mild or moderate. 
The proportion of patients with severe application-site 
events was slightly greater in the Topicaine group (7 out 
of 38, 18%) compared with the L.M.X.4 (4 out of 39, 
10%) or Betacaine (5 out of 40, 13%) groups and mostly 
consisted of application-site burning (data not shown). 
Serious AEs occurred in 6% of patients. No serious AE 
was   considered related to treatment, and no patients died 
during the study.
On the day of treatment, mean “pain now” NPRS scores 
decreased following topical anesthetic application and 
increased following patch application but on average did not 
or only slightly exceeded pre-anesthetic treatment values 
(Table 3). No significant differences in the proportion of 
n = 39
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n = 20
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NGX-4010
n = 17
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study
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Failure to return (1)
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Failure to return (2)
Other (1) Failure to return (1) Unsatisfactory
response (2) Other (2)
n = 17
Completed
study
n = 17
Completed
study
n = 17
Completed
study
n = 19
Completed
study
n = 16
Completed
study
n = 3
Withdrawn
n = 3
Withdrawn
n = 3
Withdrawn
n = 2
Withdrawn
n = 2
Withdrawn
n = 1
Withdrawn
n = 19
60 mins
NGX-4010
n = 19
60 mins
NGX-4010
n = 19
90 mins
NGX-4010
n = 20
90 mins
NGX-4010
n = 40
Betacaine
n = 38
Topicaine
n = 117
Patients treated
n = 117
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n = 20
60 mins
NGX-4010
Figure 1 Overview of patient randomization and disposition.
Table 1 Demographics and baseline characteristics
Patients L.M.X.4 
(n = 39)
Topicaine 
(n = 38)
Betacaine 
(n = 40)
Age (years), mean ± SD 63 ± 13 62 ± 12 58 ± 11
Male, % 56 61 58
Race, n (%)
  White 28 (72) 28 (74) 34 (85)
  Black or African American 5 (13) 3 (8) 2 (5)
  Asian 1 (3) 0 0
  Other 5 (13) 7 (18) 3 (8)
Neuropathic pain syndrome, n (%)
  PDN 30 (77) 29 (76) 32 (80)
  PhN 9 (23) 8 (21) 8 (20)
  hIV-DSP 0 1 (3) 0
Duration of pain (years),  
mean ± SD
5.3 ± 5.55 4.5 ± 4.90 3.8 ± 3.91
Baseline pain level,  
mean ± SD (range)
5.6 ± 1.56 
(2.5–8.2)
5.9 ± 1.44 
(3.5–8.4)
5.4 ± 1.27 
(3.0–7.8)
Baseline concomitant pain
medication usea, n (%)
24 (62) 19 (50) 23 (58)
Note: aA patient was defined as being on concomitant pain medication if he/she was 
on an anticonvulsant, non-SSRI antidepressant, or opioid that was used on day –1 
and was taken for a total duration of at least 7 consecutive days.
Abbreviations: HIV-DSP, human immunodeficiency virus-associated distal sensory 
polyneuropathy; PDN, painful diabetic neuropathy; PhN, post-herpetic neuralgia; 
SD, standard deviation; SSRI, non-selective serotonin reuptake inhibitor.
Table 2 Treatment-emergent adverse events that occurred in 
more than one patient in any of the anesthetic groups
System organ class  
preferred term
L.M.X.4 
(n = 39)
Topicaine 
(n = 38)
Betacaine 
(n = 40)
Patients reporting one or more  
treatment-emergent AEs, n (%)
23 (59) 19 (50) 23 (58)
Cardiac disorders, n (%) 2 (5) 2 (5) 0
  Cardiac failure congestive 2 (5) 0 0
Gastrointestinal disorders, n (%) 6 (15) 4 (11) 2 (5)
  Nausea 2 (5) 4 (11) 0
  Toothache 2 (5) 0 1 (3)
General disorders and  
administration-site  
conditions, n (%)
13 (33) 14 (37) 12 (30)
  Application-site burning 7 (18) 8 (21) 3 (8)
  Application-site dryness 2 (5) 0 2 (5)
  Application-site edema 0 2 (5) 0
  Application-site pain 3 (8) 5 (13) 3 (8)
  Application-site pruritus 1 (3) 1 (3) 2 (5)
  Application-site swelling 1 (3) 5 (13) 2 (5)
Infections and  
infestations, n (%)
15 (38) 7 (18) 8 (20)
  Nasopharyngitis 0 4 (11) 1 (3)
  Urinary tract infection 2 (5) 1 (3) 1 (3)
Musculoskeletal and  
connective tissue  
disorders, n (%)
10 (26) 4 (11) 6 (15)
  Muscle spasm 2 (5) 0 0
  Pain in extremity 1 (3) 2 (5) 1 (3)
Abbreviation: AE, adverse event.
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patients reporting a $33% pain increase from baseline dur-
ing the first 48 hours were observed between the L.M.X.4 and 
Topicaine or Betacaine groups. The proportion of patients 
using oral analgesics, including opioids, for treatment-related 
discomfort on days 0 through 5 was slightly greater in the 
Topicaine group (66%) compared with the L.M.X.4 (51%) or 
Betacaine (50%) groups, but the differences were not statisti-
cally significant.
Dermal irritation was generally mild and transient. The 
majority of patients had a maximum dermal assessment 
score of 2 or less, indicative of minor dermal irritation 
(Table 4). Maximum scores were typically recorded within 
2 hours after patch removal; no significant differences were 
observed between the L.M.X.4 and Topicaine or Betacaine 
groups.
Regardless of the pretreatment used, there were no 
clinically relevant changes in vital signs or any labora-
tory parameters evaluated across treatment groups. Small, 
transient blood pressure changes were observed during and 
shortly after patch application and appeared to be associated 
with treatment-related changes in pain.
Efficacy
Patients reported a mean 27.2%–34.3% reduction in pain 
during weeks 2 through 12 (Table 5), and 45%–50% of 
patients were considered to have responded to treatment 
(ie, experienced a $30% mean decrease from baseline in 
pain). The proportion of patients who achieved a $50% 
decrease in pain scores from baseline to weeks 2 through 
12 ranged from 28% to 37%. There were no significant 
  differences in pain reduction between the L.M.X.4 and 
Topicaine or Betacaine groups, and no trends were observed 
in NPRS scores between the 60- and 90-minute treatment 
groups (data not shown). Analysis of PGIC demonstrated that 
at week 12, 58%–71% of patients considered themselves to 
have improved (slightly, much, or very much) and 35%–42% 
of patients reported being much or very much improved 
(Table 5). The results of the CGIC were similar.
Discussion
Treatment with NGX-4010 in conjunction with any of the 
three topical anesthetics tested was generally well tolerated 
with a good safety profile. Nearly all patients completed at 
least 90% of the planned NGX-4010 application duration, 
regardless of the topical anesthetic product applied. As 
expected, capsaicin-related local application-site reactions 
were the most common AEs and were transient, mostly 
mild to moderate, and self-limited. Application-site events 
were adequately managed by local cooling or, if needed, by 
short-acting oral opioid analgesics (the latter were used for 
treatment-related discomfort by approximately half of all 
patients). On the day of treatment, the majority of patients 
had minor dermal irritation irrespective of the topical anes-
thetic used. In general, NGX-4010 treatment for 60 minutes 
Table 3 Change in “pain now” NPRS score from before topical 
anesthetic application on the day of treatment
L.M.X.4 
(n = 39)
Topicaine 
(n = 38)
Betacaine 
(n = 40)
25 min after patch 
application, mean ± SD
−2.2 ± 2.76 −0.9 ± 3.19 −1.9 ± 2.43
55 min after patch 
application, mean ± SD
−0.9 ± 3.72 0.6 ± 3.90 −0.3 ± 3.08
Within 5 min after patch  
removal, mean ± SD
−0.8 ± 3.29 0.1 ± 3.10 −0.1 ± 2.48
25 min after patch  
removal, mean ± SD
−0.6 ± 3.23 −0.4 ± 2.41 −1.0 ± 2.56
55 min after patch  
removal, mean ± SD
−0.5 ± 3.55 −0.7 ± 2.53 −1.1 ± 2.93
85 min after patch  
removal, mean ± SD
−0.3 ± 3.48c −0.8 ± 2.68 −1.4 ± 2.96
155 min after patch  
removal, mean ± SD
−0.2 ± 3.59 −1.2 ± 2.49 −1.5 ± 2.80
Patients reporting a  
$33% pain increase 
from baseline during 
the first 48 hours, n (%)
28 (72) 28 (74) 30 (75)
P valuea – 0.832 0.747
Patients using medication 
for treatment-related  
discomfort during  
days 0–5, n (%)
20 (51) 26 (68) 20 (50)
P valueb – 0.195 0.922
Notes: aP value was computed from a Cochran–Mantel–haenszel test, adjusted for 
treatment duration, comparing the proportions between the L.M.X.4 group and the 
other two topical anesthetic groups; bP value was computed from a chi-squared test 
comparing the proportions between the L.M.X.4 group and the other two topical 
anesthetic groups; c38 patients only.
Abbreviation: SD, standard deviation.
Table 4 Maximum dermal assessment scores from removal of 
patch through termination
Score (0 to 7)a L.M.X.4 
(n = 39)
Topicaine 
(n = 38)
Betacaine 
(n = 40)
0, n (%) 10 (26) 10 (26) 14 (35)
1, n (%) 10 (26) 10 (26) 11 (28)
2, n (%) 15 (38) 17 (45) 13 (33)
3, n (%) 2 (5) 0 1 (3)
4, n (%) 1 (3) 1 (3) 1 (3)
5, n (%) 1 (3) 0 0
6, n (%) 0 0 0
7, n (%) 0 0 0
P valueb – 0.916 0.284
Notes: a0 = no evidence of irritation; 1 = minimal erythema, barely perceptible; 
2 = definite erythema, readily visible; minimal edema or minimal papular response; 
3 = erythema and papules; 4 = definite edema; 5 = erythema, edema, and papules; 
6 = vesicular eruption; 7 = strong reaction spreading beyond test site.  bP value 
was computed from a Cochran–Mantel–haenszel test comparing distribution of 
maximum score (0, 1, $2) between the L.M.X.4 group and the other two topical 
anesthetics groups.
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in prolonged pain relief for up to 12 weeks following a 
single application of NGX-4010 in all groups; other efficacy 
  endpoints also showed similar relief of pain across the   different 
pretreatment groups. Mean NPRS scores were reduced from 
baseline by approximately 30% in all groups, which is similar 
to the degree of pain relief reported previously in Phase III 
clinical trials of NGX-4010 in patients with PHN that utilized 
a 60-minute pretreatment with L.M.X.4.15,18
Limitations of the study included the lack of a control 
group. In addition, the sample size was insufficient to detect 
small differences between the topical lidocaine formulations 
in terms of tolerability and efficacy of NGX-4010. However, 
the study was sufficiently powered to detect a difference of 
20% in the proportion of subjects completing at least 90% 
of intended duration between the L.M.X.4-treated group 
and each of the other topical anesthetic groups. As only a 
single patient was not able to tolerate the full duration of 
NGX-4010 application, and changes in mean NPRS scores 
were within the range reported in previous clinical trials in 
patients with PHN,15,18 the results from this study seem to 
indicate that when used as a pretreatment for NGX-4010, all 
of the topical formulations tested are similarly effective and 
do not impact on the efficacy of NGX-4010.
In conclusion, treatment with NGX-4010 in conjunction 
with any of the three topical anesthetics tested was generally 
safe and well tolerated. Regardless of the topical anesthetic 
used, there were no significant differences in tolerability. 
Relief of peripheral neuropathic pain from a single applica-
tion of NGX-4010 was similar in the three topical anesthetic 
groups and comparable to the level of pain relief reported 
in previous Phase III clinical trials of NGX-4010 in patients 
with PHN.15,18 As few differences were seen between the 
three topical anesthetics tested and each topical anesthetic 
appeared to be a suitable pretreatment for NGX-4010, the 
results of this study suggest that clinicians can select a topical 
anesthetic formulation for pretreatment according to local 
clinical practice, product availability, and cost.
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Table 5 Efficacy of NGX-4010
L.M.X.4 Topicaine Betacaine
NPRS scores
Baseline, LS mean ± SE 5.6 ± 0.23 5.9 ± 0.23 5.4 ± 0.23
Weeks 2–12, n 39 38 40
  Actual (LS mean ± SE) 3.9 ± 0.32 3.8 ± 0.33 4.0 ± 0.32
    Change from baseline  
(LS mean ± SE)
−1.7 ± 0.32 −1.8 ± 0.33 −1.6 ± 0.32
    Percentage change from  
baseline (LS mean ± SE)
−31.8 ± 5.61 −34.3 ± 5.72 −27.2 ± 5.56
 P  valuea – 0.757 0.563
Patients with $30%  
decrease from baseline  
to weeks 2–12, n (%)
18 (46) 19 (50) 18 (45)
 P  valueb – 0.588 0.864
Patients with $50%  
decrease from baseline  
to weeks 2–12, n (%)
13 (33) 14 (37) 11 (28)
 P  valueb – 0.610 0.608
PGIC
Week 12, n 36 37 38
Much improved (very  
much, much), n (%)
14 (39) 13 (35) 16 (42)
Improved (very much,  
much, slightly), n (%)
21 (58) 24 (65) 27 (71)
Notes: P value was computed using ANCOVA to test for difference between the 
L.M.X.4 group and the other two topical anesthetic groups. bP value was computed 
using logistic regression to test for difference between the L.M.X.4 group and the 
other two topical anesthetic groups.
Abbreviations: ANCOVA, analysis of covariance; LS mean, least squares mean; 
NPRS, Numeric Pain Rating Scale; PGIC, Patient Global Impression of Change; SE, 
standard error.
was better tolerated than treatment for 90 minutes. In each 
anesthetic group, more patients treated with NGX-4010 for 
90 minutes used medication for treatment-related discom-
fort than those treated for 60 minutes; patients treated for 
90 minutes generally reported larger pain increases during 
the treatment procedure compared with those treated for 
60 minutes; and maximum dermal assessment scores were 
generally lower in patients treated for 60 minutes compared 
with patients treated for 90 minutes (data not shown).
The incidence and severity of application-site events 
and the proportion of patients using oral analgesics for 
treatment-related discomfort were slightly greater following 
pretreatment with Topicaine than following pretreatment 
with L.M.X.4 or Betacaine. However, differences in medica-
tion use were not statistically significant and likely related 
to the relatively small sample size.
Since the systemic absorption of capsaicin after   application 
of NGX-4010 is minimal,24 the lack of effect of NGX-4010 
on any laboratory parameter evaluated was expected.
The analyses of NPRS scores and PGIC indicate that the 
selection of topical anesthetic had no influence over the pain 
relief obtained with NGX-4010. Indeed NGX-4010 resulted 
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